Atypical Hyperplasia of the Breast — Risk Assessment and Management Options英文资料.PDFVIP

T h e n e w e ngl a nd j o u r na l o f m e dic i n e s p e c i a l r e p o r t Atypical Hyperplasia of the Breast — Risk Assessment and Management Options Lynn C. Hartmann, M.D., Amy C. Degnim, M.D., Richard J. Santen, M.D., William D. Dupont, Ph.D., and Karthik Ghosh, M.D. Breast biopsies are commonly performed to eval- included in many high-risk guidelines. For ex- uate mammographic or palpable findings that ample, screening magnetic resonance imaging are of concern, and the majority reveal benign (MRI) is not routinely recommended for these findings. More than 1 million of the breast biop- women.16 In addition, studies of the use of che- sies that are performed annually in the United mopreventive agents show that only a small mi- 1 17 States are found to be benign. On the basis of nority of high-risk women take these drugs, the histologic findings, it is possible to stratify despite randomized clinical trials showing sub- women with benign biopsy findings into groups stantial benefit specifically for women with with significantly different risks of later breast atypical hyperplasia. cancer.2,3 Atypical hyperplasia is a high-risk be- Because of the high-risk